Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 11, 2010 - Issue 18
Submit an article Journal homepage
244
Views
17
CrossRef citations to date
0
Altmetric
Original Research

An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN

Sebastian M Schellong Municipal Hospital of Dresden Friedrichstadt, 01067 Dresden, Germany +49 351 4801120; +49 351 4801129; [email protected]
,
Sylvia Haas Institut für experimentelle Onkologie und Therapieforschung, Technische Universität München, Germany
,
Andreas Greinacher Institut für Immunologie und Tranfusionsmedizin, Ernst-Moritz-Arndt Universität Greifswald,Germany
,
Uta Schwanebeck Koordinierungszentrum für Klinische Studien, TU Dresden, Dresden, Germany
,
Christian Sieder Novartis Pharma GmbH, Nürnberg, Germany
,
Claudia Abletshauser Novartis Pharma GmbH, Nürnberg, Germany
,
Peter Bramlage Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany
&
Hanno Riess Campus Virchow Klinikum Berlin, Germany
 show all
Pages 2953-2961 | Published online: 18 Oct 2010

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Vicki Laskier, Holly Guy, Mark Fisher, W. Richey Neuman, Iwona Bucior, Alexander T. Cohen & Shijie Ren. (2019) Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis. Journal of Medical Economics 22:10, pages 1063-1072.
Read now
Christopher Dooley, Rajbir Kaur & Diana M. Sobieraj. (2014) Comparison of the efficacy and safety of low molecular weight heparins for venous thromboembolism prophylaxis in medically ill patients. Current Medical Research and Opinion 30:3, pages 367-380.
Read now

Articles from other publishers (15)

Ruben J Eck, Tessa Elling, Alex J Sutton, Jørn Wetterslev, Christian Gluud, Iwan C C van der Horst, Reinold O B Gans, Karina Meijer & Frederik Keus. (2022) Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. BMJ, pages e070022.
Crossref
Simone Birocchi, Marco Manzoni, Gian Marco Podda, Giovanni Casazza & Marco Cattaneo. (2020) High rates of pulmonary artery occlusions in COVID‐19. A meta‐analysis. European Journal of Clinical Investigation 51:1.
Crossref
Holger J. SchünemannMary CushmanAllison E. BurnettSusan R. KahnJan Beyer-WestendorfFrederick A. Spencer, Suely M. RezendeNeil A. ZakaiKenneth A. BauerFrancesco DentaliJill LansingSara Balduzzi, Andrea DarziGian Paolo MorganoIgnacio Neumann, Robby NieuwlaatJuan J. Yepes-NuñezYuan ZhangWojtek Wiercioch. (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Advances 2:22, pages 3198-3225.
Crossref
Gary H. Lyman, Eva Culakova, Marek S. Poniewierski & Nicole M. Kuderer. (2018) Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thrombosis Research 164, pages S112-S118.
Crossref
Fan Ye, Lauren N. Bell, Joseph Mazza, Arthur Lee & Steven H. Yale. (2016) Variation in Definitions of Immobility in Pharmacological Thromboprophylaxis Clinical Trials in Medical Inpatients: A Systematic Review. Clinical and Applied Thrombosis/Hemostasis 24:1, pages 13-21.
Crossref
H. Zöllner, R. Jouni, S. Panzer, A. Khadour, L. Janzen, J. Wesche, M. ten Berg, S. Schellong, A. Heinken, A. Greinacher & T. Bakchoul. (2017) Platelet activation in the presence of neutral protamine Hagedorn insulin: a new feature of antibodies against protamine/heparin complexes. Journal of Thrombosis and Haemostasis 15:1, pages 176-184.
Crossref
Alessandro Squizzato, Federico Lussana, Walter Ageno & Marco Cattaneo. (2016) Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review. Internal and Emergency Medicine 11:3, pages 467-476.
Crossref
Deepali N Tukaye, Heidi Brink & Ragavendra Baliga. (2016) Venous thromboembolism in cancer patients: risk assessment, prevention and management. Future Cardiology 12:2, pages 221-235.
Crossref
Olumide B Gbolahan, Trista J Stankowski-Drengler, Abiola Ibraheem, Jessica M Engel & Adedayo A Onitilo. (2015) Management of chemotherapy-induced thromboembolism in breast cancer. Breast Cancer Management 4:4, pages 187-198.
Crossref
Rajnish Joshi, Saurabh Saigal, Jai Sharma & Dinesh Singh. (2014) Thrombo-prophylaxis in acutely ill medical and critically ill patients. Indian Journal of Critical Care Medicine 18:6, pages 382-391.
Crossref
Raza Alikhan, Rachel Forster & Alexander T Cohen. (2014) Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Cochrane Database of Systematic Reviews 2018:2.
Crossref
Nicole M. Kuderer & Gary H. Lyman. (2014) Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thrombosis Research 133, pages S122-S127.
Crossref
Sherab Bhutia & Peng F Wong. (2013) Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. Cochrane Database of Systematic Reviews.
Crossref
Gary H. LymanAlok A. KhoranaNicole M. KudererAgnes Y. LeeJuan Ignacio ArcelusEdward P. BalabanJeffrey M. ClarkeChristopher R. FlowersCharles W. FrancisLeigh E. GatesAjay K. KakkarNigel S. KeyMark N. LevineHoward A. LiebmanMargaret A. TemperoSandra L. WongAnn Alexis PrestrudAnna Falanga. (2013) Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology 31:17, pages 2189-2204.
Crossref
Gary H. LymanAlok A. KhoranaAnna Falanga. (2013) Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book:33, pages e337-e345.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.